MarketCap
Supernus Pharmaceuticals SUPN
€ 25.62
3.68%
Facebook
X
Telegram
Supernus Pharmaceuticals EV/EBITDA | SUPN
EV/EBITDA Jährlich Supernus Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 115 | 12.7 | 25.9 | 20.6 | 19.5 | 10.5 | 8.97 | 13.6 | 18 | 21.1 | 27.5 | 13.9 | -5.12 | -2.83 | - | 0.61 | - |
Jährliche Entwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 115 | -5.12 | 20 |
EV/EBITDA anderer Aktien in der Pharmaeinzelhändler
| Name | EV/EBITDA | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Kodiak Sciences
KOD
|
-9.31 | $ 108.01 | 0.85 % | $ 5.75 B |  USA |
 |
Karyopharm Therapeutics
KPTI
|
-3.77 | $ 0.02 | -54.5 % | $ 219 | USA |
 |
FSD Pharma
HUGE
|
-0.271 | - | 5743.5 % | $ 69.7 M |  Canada |
 |
BioAtla
BCAB
|
-0.888 | $ 1.74 | 0.64 % | $ 102 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
9.61 | - | - | $ 3.85 B | USA |
 |
UroGen Pharma Ltd.
URGN
|
-8.98 | $ 25.32 | -3.78 % | $ 1.22 B |  Israel |
 |
Catalyst Biosciences
CBIO
|
70.6 | $ 13.91 | 1.9 % | $ 1.24 B | USA |
 |
ARCA biopharma
ABIO
|
0.248 | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
1.28 | - | 4.01 % | $ 150 M | Canada |
 |
ADiTx Therapeutics
ADTX
|
-0.487 | - | - | $ 374 | USA |
 |
Aeterna Zentaris
AEZS
|
-0.963 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-0.164 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
0.111 | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
-45.5 | - | 1.93 % | $ 17.4 M | USA |
 |
Aileron Therapeutics
ALRN
|
-0.0795 | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
1.19 | - | 4.14 % | $ 49.1 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
52.9 | - | - | $ 5.18 B | USA |
 |
Athira Pharma
ATHA
|
0.0485 | - | - | $ 269 M | USA |
 |
AVROBIO
AVRO
|
2.95 | - | 1083.1 % | $ 745 M | USA |
 |
AstraZeneca PLC
AZN
|
3.06 | - | - | $ 96.9 B |  Britain |
 |
Brainstorm Cell Therapeutics
BCLI
|
-1.13 | - | -2.5 % | $ 5.88 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-1.22 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
EyePoint Pharmaceuticals
EYPT
|
0.177 | $ 0.39 | 9.06 % | $ 28.6 K | USA |
 |
Bio-Path Holdings
BPTH
|
-0.864 | - | - | $ 100 K | USA |
 |
Cara Therapeutics
CARA
|
0.36 | - | -3.03 % | $ 260 M | USA |
 |
ChromaDex Corporation
CDXC
|
-2.07 | - | -0.88 % | $ 598 M | USA |
 |
Caladrius Biosciences
CLBS
|
0.709 | - | -16.75 % | $ 25.8 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
0.257 | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
0.257 | - | -4.36 % | $ 27 M | USA |
 |
Diffusion Pharmaceuticals
DFFN
|
0.127 | - | 11.68 % | $ 8.97 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
-11 | - | -5.68 % | $ 8.28 M | USA |
 |
Enochian Biosciences
ENOB
|
-2.01 | - | - | $ 40.5 M | USA |
 |
Esperion Therapeutics
ESPR
|
19.2 | - | - | $ 661 M | USA |
 |
Evofem Biosciences
EVFM
|
26.3 | - | 7.55 % | $ 38.1 M | USA |
 |
Eyenovia
EYEN
|
-0.0912 | - | 49.81 % | $ 13.2 M | USA |
 |
FibroGen
FGEN
|
-1.49 | - | - | $ 889 M | USA |
 |
Homology Medicines
FIXX
|
-1.65 | - | 0.77 % | $ 53.4 M | USA |
 |
Amicus Therapeutics
FOLD
|
121 | - | - | $ 4.47 B | USA |
 |
Frequency Therapeutics
FREQ
|
-0.342 | - | - | $ 528 M | USA |
|
Galecto
GLTO
|
1.13 | - | - | $ 762 M |  Danmark |
 |
GlycoMimetics
GLYC
|
1.15 | - | 9357.83 % | $ 1.01 B | USA |
 |
Graybug Vision
GRAY
|
-0.378 | - | -11.23 % | $ 9.65 M | USA |
|
Galera Therapeutics
GRTX
|
2.25 | - | -32.59 % | $ 7.61 M | USA |
 |
Happiness Biotech Group Limited
HAPP
|
0.512 | - | 1.35 % | $ 17.8 M |  China |
 |
Novavax
NVAX
|
6.05 | $ 10.15 | -6.8 % | $ 1.64 B | USA |
 |
Hepion Pharmaceuticals
HEPA
|
0.252 | - | -18.79 % | $ 39.3 K | USA |
 |
Hoth Therapeutics
HOTH
|
-0.517 | - | - | $ 18.8 M | USA |
 |
IMARA
IMRA
|
0.69 | - | 15.96 % | $ 663 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
-8.5 | - | - | $ 1.45 B | Britain |
 |
KemPharm
KMPH
|
-1.15 | - | -0.34 % | $ 200 M | USA |